ZEPBOUND VS WEGOVY AT A GLANCE
Quick Comparison
Zepbound produces 47% more weight loss than Wegovy based on the 2025 SURMOUNT-5 head-to-head trial (20.2% vs 13.7% at 72 weeks).[2] Both are FDA-approved weekly injections for chronic weight management—but Zepbound's dual-hormone mechanism delivers superior results. Here's the complete comparison:
| Feature | Zepbound | Wegovy |
|---|---|---|
| Active Ingredient | Tirzepatide | Semaglutide |
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA Approval | Weight management[8], Sleep apnea (OSA) | Weight management, CV risk reduction[12] |
| How It Works | Dual GIP/GLP-1 agonist | GLP-1 agonist only |
| Avg. Weight Loss | ~20% at 72 weeks | ~15% at 68 weeks |
| Dosing | Weekly injection (2.5–15 mg) | Weekly injection (0.25–2.4 mg) or daily pill (25 mg) |
| Oral Option | Not available | Yes — FDA approved Dec 2025[9] |
| List Price | ~$1,086/month | ~$1,349/month |
| Insurance Coverage | Limited (weight loss exclusions common) | Limited (weight loss exclusions common) |
Bottom line: Zepbound shows greater weight loss in clinical trials (~20% vs ~15%), has a lower list price, and works through a dual hormone mechanism.[7] However, Wegovy has a longer track record, more cardiovascular outcome data, and now offers an oral tablet option (FDA-approved Dec 2025).[9]
MAKING YOUR DECISION
Wegovy vs Zepbound: Which Is Right for You?
Whether you're searching for "Wegovy vs Zepbound" or "Zepbound vs Wegovy," the core question is the same: which medication will help you lose more weight with better insurance coverage and fewer side effects?
The answer depends on your specific situation:
- If maximum weight loss is your priority: Zepbound's dual-hormone mechanism produced 47% more weight loss in head-to-head trials
- If your insurance covers one but not the other: Coverage varies widely—check your formulary first
- If you've already tried Wegovy: Switching to Zepbound may provide additional weight loss due to the different mechanism
- If cardiovascular health is a concern: Wegovy has more long-term cardiovascular outcome data (SELECT trial)
Below, we break down the clinical evidence, side effects, costs, and insurance coverage to help you make an informed decision with your doctor.
MECHANISM OF ACTION
How They Work
Both medications mimic natural gut hormones that regulate appetite—but Zepbound targets two pathways while Wegovy targets one.
Zepbound (Tirzepatide)
Dual GIP/GLP-1 Receptor Agonist
- Mimics both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1)
- Reduces appetite through two complementary pathways
- Improves insulin sensitivity through dual mechanism
- May enhance fat metabolism beyond GLP-1 alone
Wegovy (Semaglutide)
GLP-1 Receptor Agonist
- Mimics only GLP-1 (glucagon-like peptide-1)
- Reduces appetite by signaling fullness to the brain
- Slows stomach emptying
- Proven cardiovascular benefits (SELECT trial)
Why the Dual Mechanism Matters
GIP and GLP-1 work together to produce better results than either alone. While GLP-1 reduces appetite and slows digestion, GIP helps your body process food more efficiently. This combined action explains why Zepbound produces more weight loss than Wegovy in head-to-head trials.[1]
CLINICAL TRIAL DATA
Weight Loss Results
Both medications have been studied extensively. Here's how they compare in clinical trials:
SURMOUNT Trials (Zepbound)[3]
| Trial | Population | Weight Loss (15mg) | vs. Placebo |
|---|---|---|---|
| SURMOUNT-1 | Adults with obesity (no diabetes) | 20.9% at 72 weeks | vs. 3.1% |
| SURMOUNT-2 | Adults with obesity + T2D | 14.7% at 72 weeks | vs. 3.2% |
STEP Trials (Wegovy)[4]
| Trial | Population | Weight Loss (2.4mg) | vs. Placebo |
|---|---|---|---|
| STEP 1 | Adults with obesity (no diabetes) | 14.9% at 68 weeks | vs. 2.4% |
| STEP 2 | Adults with obesity + T2D | 9.6% at 68 weeks | vs. 3.4% |
Head-to-Head Comparison (2025)
Direct Comparison Trial Results
In a 2025 head-to-head clinical trial, Zepbound achieved 20.2% mean weight loss compared to 13.7% with Wegovy at 72 weeks. Additionally, 64.6% of Zepbound users achieved ≥15% weight loss vs. 40.1% with Wegovy.[2]
| Weight Loss Milestone | Zepbound | Wegovy |
|---|---|---|
| ≥10% weight loss | 81.6% | 60.5% |
| ≥15% weight loss | 64.6% | 40.1% |
| ≥25% weight loss | 31.6% | 16.1% |
Source: SURMOUNT-5 head-to-head trial (72 weeks)[2]
TOLERABILITY COMPARISON
Side Effects
Both medications cause similar gastrointestinal side effects, especially during dose escalation. These typically improve over time as your body adjusts. The following rates are from the SURMOUNT-5 head-to-head trial:[2]
| Side Effect | Zepbound | Wegovy |
|---|---|---|
| Nausea | 43.6% | 44.4% |
| Constipation | 27.0% | 28.5% |
| Diarrhea | 23.5% | 23.4% |
| Vomiting | 15.0% | 21.3% |
| Injection site reactions | 8.6% | 0.3% |
Serious Risks (Both Medications)
Important Safety Information
Both Zepbound and Wegovy carry warnings for:
- Pancreatitis (inflammation of the pancreas)
- Gallbladder problems including gallstones
- Acute kidney injury (especially with dehydration)
- Thyroid tumors (boxed warning—avoid if you or family members have had medullary thyroid cancer or MEN 2 syndrome)
Key finding: In the SURMOUNT-5 head-to-head trial, GI side effect rates were remarkably similar between the two medications. Both improve with gradual dose escalation, and most symptoms are mild-to-moderate and occur primarily during the dose-escalation phase.[5]
PRICING & SAVINGS PROGRAMS
Cost Comparison
Without insurance or discounts, both medications are expensive—but Zepbound has a lower list price and more aggressive savings programs.
| Cost Factor | Zepbound | Wegovy |
|---|---|---|
| List Price (monthly) | $1,086.37 | $1,349.02 |
| Annual Cost (list) | ~$12,700 | ~$16,200 |
| Manufacturer Savings Card | as little as $25 (with commercial coverage) | Up to $100 per 1-month fill (with commercial coverage) |
| Cash Pay Options | LillyDirect vials: $299–$449/month* | NovoCare options available |
Zepbound Savings Card
Commercially insured patients may pay as little as $25/month with the Zepbound Savings Card. Even if your insurance doesn't cover Zepbound, the LillyDirect program offers single-dose vials: $299 (2.5mg), $399 (5mg), or $449/month for maintenance doses (7.5-15mg with loyalty program).[6]
Note: Savings programs have varying terms—verify current offers at zepbound.lilly.com and NovoCare.com. Wegovy pill self-pay: $149–$299/month by dose.
For comprehensive pricing details, see our Zepbound cost guide.
WHY YOUR PBM MATTERS MORE THAN YOUR INSURER
Insurance Coverage: The PBM Factor
Which drug your insurance prefers increasingly depends on your pharmacy benefit manager (PBM)—not just your insurer name.
CVS Caremark: Zepbound Is Preferred Again
From July 1, 2025 to September 30, 2026, CVS Caremark's most common commercial template formularies preferred Wegovy, and Zepbound was nonpreferred or excluded on some of them (not all).[13] Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize), alongside Wegovy. Employers and plans can customize their formulary, so some plans may still exclude Zepbound: check your own plan's formulary.
Coverage by PBM (2026)
| PBM | Zepbound Status | Wegovy Status | Who Uses This PBM |
|---|---|---|---|
| CVS Caremark | Preferred again since October 1, 2026 (some plans may still exclude it) | Preferred | Aetna, many employers |
| Express Scripts | Covered with PA on many plans | Covered with PA | Cigna, some BCBS |
| OptumRx | Varies by employer | Varies by employer | UnitedHealthcare |
How to find your PBM: Check your pharmacy benefit card—the PBM is often listed, or call the number on your card to ask.
Wegovy's Cardiovascular Coverage Advantage
Wegovy has a unique coverage pathway that Zepbound doesn't: cardiovascular risk reduction.
The SELECT Trial Advantage
The SELECT trial showed Wegovy reduces major cardiovascular events by 20% in patients with obesity and established cardiovascular disease.[12] Based on this data, the FDA approved Wegovy injection on March 8, 2024 to reduce CV risk in adults with established cardiovascular disease and either obesity or overweight (the tablets’ CV indication came with their December 22, 2025 approval). Some insurers now cover Wegovy for CV risk reduction even if they exclude weight loss drugs. If you have heart disease or high CV risk, ask your doctor about this pathway.
What This Means for Your Choice
Consider Zepbound If:
- Your PBM is Express Scripts or OptumRx
- Your employer plan explicitly covers Zepbound
- You have sleep apnea (FDA-approved indication)
- Maximum weight loss is your priority
Consider Wegovy If:
- Your plan's formulary prefers Wegovy
- You have cardiovascular disease or high CV risk
- Your plan excluded Zepbound but may cover CV drugs
- You need the longer safety track record (2021)
For detailed coverage by insurer, see our insurance coverage guides.
Your GLP-1 coverage,
denied approved
If your coverage is denied, Honest Care can help you appeal with personalized, evidence-backed letters.
Need help with coverage?
Get Started FreeMAKING YOUR DECISION
Which Should You Choose?
The "best" medication depends on your individual circumstances. Here's how to think about the decision:
Choose Zepbound if...
- Maximum weight loss is your priority — Clinical trials show ~7% more weight loss with Zepbound
- You have sleep apnea — Zepbound is FDA-approved for obesity-related OSA
- Cost matters — Lower list price and $25/month savings card available
- You haven't tried GLP-1 medications before — Dual mechanism may provide better results as first-line therapy
Choose Wegovy if...
- You have heart disease or high cardiovascular risk — The SELECT trial showed a 20% reduction in heart attacks, strokes, and related events[12]
- Your insurance covers it but not Zepbound — Wegovy has been on the market longer with more formulary placements
- You prefer a proven track record — More long-term safety data available since 2021 approval
- You've had success with Ozempic — Wegovy is the same active ingredient (semaglutide) at a higher dose
- You prefer a pill over injections — Oral Wegovy (daily tablet) is FDA-approved and launching January 2026[9]
Talk to your doctor if...
- You have a history of pancreatitis or gallbladder disease
- You or a family member has had medullary thyroid cancer or MEN 2
- You're pregnant, planning pregnancy, or breastfeeding
- You have severe gastrointestinal conditions
- You're taking other diabetes medications
The Practical Reality
For many patients, the choice comes down to insurance coverage and cost. Both are highly effective medications—getting one covered and affordable is often more important than which specific one you take. Work with your healthcare provider to find the option that's accessible for you.
ZEPBOUND VS WEGOVY
Frequently Asked Questions
No, they are different medications. Wegovy contains semaglutide (GLP-1 only), while Zepbound contains tirzepatide (dual GIP + GLP-1). They work through different mechanisms, and Zepbound produces about 47% more weight loss in head-to-head trials (20.2% vs 13.7%). However, both are FDA-approved weekly injections for chronic weight management.
In the SURMOUNT-5 head-to-head trial, Zepbound achieved 20.2% mean weight loss vs 13.7% for Wegovy at 72 weeks—about 47% more weight loss. This translates to roughly 52 lbs vs 34 lbs for a 250 lb patient. Both are highly effective, but the dual GIP/GLP-1 mechanism gives Zepbound a measurable advantage.
Zepbound's dual mechanism is the key difference. While Wegovy activates only GLP-1 receptors, Zepbound activates both GLP-1 and GIP receptors. These two hormones work synergistically—GIP appears to enhance the appetite-suppressing and metabolic effects of GLP-1, leading to greater overall weight reduction.
From July 1, 2025 to September 30, 2026, CVS Caremark's most common commercial template formularies preferred Wegovy, and Zepbound was nonpreferred or excluded on some of them (not all). Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize), alongside Wegovy. Employers and plans can customize their formulary, so some plans may still exclude Zepbound. If you have CVS Caremark and were denied Zepbound, check your plan's current formulary, ask your doctor about Wegovy—or appeal using our appeals guide.
Side effect profiles are similar. Both cause primarily GI effects (nausea, diarrhea, constipation) that typically improve over time. Zepbound may cause slightly more nausea at higher doses, while Wegovy may cause more constipation. Individual responses vary—if you had issues with one, you may tolerate the other better.
No. Never take Zepbound and Wegovy (or any two GLP-1 medications) together. They work through similar mechanisms, and combining them increases side effect risk without proven benefit. Choose one medication under your doctor's guidance.
Wegovy now has an oral option. The FDA approved oral semaglutide for weight loss (Wegovy in pill form) on December 22, 2025, with a January 2026 launch.[9] The OASIS 4 trial showed 14.4% weight loss at 64 weeks, with 30% of patients achieving ≥20% weight loss—comparable to the injectable.[10] Zepbound does not currently have an oral option. Oral tirzepatide is in clinical trials but not yet FDA-approved. If avoiding injections is important, oral Wegovy gives Wegovy a significant advantage.
Learn More About These Medications
Explore complete guides for coverage, costs, and appeals:
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get startedWHAT'S CHANGING
Zepbound vs Wegovy: 2026 Outlook
2026: Both Options Expanding Access
Coverage for both Zepbound and Wegovy is expected to expand in 2026 as more employers add GLP-1 benefits. Surveys suggest more than a quarter of large employers may cover GLP-1s for obesity in 2026, up from around one-fifth in 2025.
New in 2026: Oral Wegovy
Wegovy gains a major advantage: The daily oral tablet was FDA-approved December 22, 2025 and launched January 5, 2026.[9] The OASIS 4 trial showed 14.4% average weight loss at 64 weeks, with 30% of participants achieving ≥20% weight loss—comparable to the injectable version.[10] For patients who dislike needles, oral Wegovy may be a game-changer. Pricing: $149/month for the 1.5 mg starting dose, $299/month for maintenance (25mg), or as low as $25/month with commercial insurance.[11]
Coverage Considerations
- Wegovy has first-mover advantage — FDA-approved for weight loss since 2021; more established formulary positions
- Step therapy requirements — Some plans may require trying another drug first; check your plan’s criteria
- Wegovy CV indication — FDA-approved (injection 2024, tablets 2025) to reduce cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight; may improve coverage for that use
Cash Pay Options
If insurance doesn't cover either medication:
- Zepbound via LillyDirect: $299 (2.5mg), $399 (5mg), $449 (7.5-15mg with loyalty) per month for vials
- Wegovy via NovoCare self-pay: $349/month ($399 for Wegovy HD 7.2 mg)
References
- Rosenstock J, et al. (2021). "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide." Lancet. https://pubmed.ncbi.nlm.nih.gov/34170647/
- Wilding JPH, et al. (2025). "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity." N Engl J Med. SURMOUNT-5 trial. https://pubmed.ncbi.nlm.nih.gov/40353578/
- Jastreboff AM, et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. SURMOUNT-1. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Wilding JPH, et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. STEP 1. https://pubmed.ncbi.nlm.nih.gov/33567185/
- GoodRx. (2025). "Zepbound vs. Wegovy: Differences Between Weight-Loss Medications." https://www.goodrx.com/conditions/weight-loss/zepbound-vs-wegovy
- Eli Lilly. (2024). "Zepbound Savings Card and Support." https://zepbound.lilly.com/savings
- Aamir AB, et al. (2025). "Comparative Efficacy of Tirzepatide vs. Semaglutide." PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12151102/
- U.S. FDA. (2023). "FDA Approves New Medication for Chronic Weight Management." https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
- Novo Nordisk. (2025). "Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults." Press release, December 22, 2025. PRNewswire
- Wharton S, et al. (2025). "Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity." N Engl J Med. 2025;393(11):1077-1087. OASIS 4 trial. https://pubmed.ncbi.nlm.nih.gov/40934115/
- NovoCare. (2026). "Wegovy® (semaglutide) Savings and Coverage Support." https://www.novocare.com/patient/medicines/wegovy.html
- Lincoff AM, et al. (2023). "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med. 2023;389(24):2221-2232. SELECT trial (PMID 37952131). https://pubmed.ncbi.nlm.nih.gov/37952131/
- CVS Caremark. (2025). "Enabling Wider Access to Effective Weight Management Treatment." Formulary update, July 2025. https://business.caremark.com/what-we-do/cost-management/formulary/glp-1s.html
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.